GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
MWN-AI** Summary
GT Biopharma, Inc. has announced the FDA's clearance of its Investigational New Drug (IND) application for GTB-5550, a novel TriKE® (Tri-specific Killer Engager) targeting B7-H3 in solid tumors. This marks the third TriKE® IND approved for the company, underscoring its commitment to advancing innovative therapies in immuno-oncology. The Phase 1 clinical trial is anticipated to commence in mid-2026, allowing enrollment of patients with various solid tumors expressing B7-H3, particularly focusing on those with advanced prostate, ovarian, and pancreatic cancers that have proven resistant to standard treatments.
GTB-5550 utilizes a unique nanobody construct designed to enhance the efficacy of natural killer (NK) cells against cancerous cells. It engages the CD16 receptor on NK cells and incorporates a wildtype IL-15 component for NK cell proliferation while specifically targeting the B7-H3 antigen found in a high percentage of metastatic castration-resistant prostate cancers. Dr. Emmanuel Antonarakis, MD, noted the unmet need for effective therapies in patients expressing B7-H3, emphasizing the trial's significance.
The Phase 1 trial includes a dose-escalation segment to identify the maximum tolerated dose, with subsequent expansion phases examining safety and preliminary anti-tumor activity across multiple cancer types. GT Biopharma has reported an unaudited pro forma cash balance of approximately $9 million as of January 31, 2026, expected to extend their cash runway into Q4 2026.
This clearance highlights GT Biopharma’s dedication to pioneering immune-based cancer treatments and sets the stage for potentially impactful advancements in solid tumor therapies. For more details on the company's developments, interested parties can visit their website at gtbiopharma.com.
MWN-AI** Analysis
GT Biopharma's recent announcement regarding FDA clearance for the investigational new drug (IND) application for GTB-5550 marks a significant milestone in its ongoing development of innovative cancer therapies. The company's proprietary TriKE® platform aims to engage natural killer (NK) cells in targeting solid tumors that express the B7-H3 protein, a critical antigen in many cancers.
With the Phase 1 basket trial expected to initiate in mid-2026, investors should consider a few key factors. Firstly, the dual nanobody design of GTB-5550, which allows for subcutaneous administration, highlights its potential for patient-friendly treatment protocols—a significant advantage in oncology. Furthermore, preliminary enthusiasm surrounding GTB-3650's performance in treating acute myeloid leukemia (AML) patients suggests positive prospects for GTB-5550 in solid tumors.
Financially, GT Biopharma holds an unaudited proforma cash balance of approximately $9 million as of January 31, 2026. This cash position is pivotal as it is anticipated to fund operations through Q4 2026, allowing the company to execute its clinical trials without immediate pressure for additional capital. Investors should evaluate the company’s cash flow management and the potential need for capital raises post-2026.
Analysts should also take note of the competitive landscape—B7-H3 is a hot target in the oncology sector, with various companies researching its potential. Therefore, maintaining a competitive edge in development timelines and clinical results will be crucial for GT Biopharma.
In summary, while the IND clearance and solid cash runway present opportune signals for investment, one should remain cognizant of the competitive environment and the inherent risks associated with clinical trials. Investors may consider this a good entry point, bearing in mind the significance of upcoming trial results and additional funding requirements in the future.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026
Phase 1 protocol allows multiple solid tumor types known to express B7-H3
Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026
SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced FDA clearance of its IND application for GTB-5550, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to initiate in mid-2026.
“FDA clearance of our third TriKE® IND, GTB-5550, represents a defining moment for GT Biopharma as we bring another NK cell engager into the clinic”, said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “We expect to commence enrollment of the Phase 1 basket trial in mid-2026. While the phase I trial is open to patients with common solid tumors that express B7-H3, in the dose-escalation component we will prioritize enrollment for advanced prostate, ovarian, and pancreatic cancer patients who have failed standard therapies. Based on the encouraging trends we have seen from our ongoing Phase 1 trial with GTB-3650 in AML patients, we are even more enthusiastic about the potential benefits of GTB-5550 treatment in patients with solid tumors known to express B7-H3.”
GTB-5550 is a camelid (cam) anti-CD16/WT IL-15/cam anti-B7-H3 tri-specific natural killer (TriKE) cell engager, with a single chain recombinant TriKE® comprised of three components joined by flexible linkers: 1) a nanobody arm that engages the CD16 activating receptor (camelid anti-CD16) on natural killer (NK) cells; 2) a wildtype IL-15 (WT IL-15) linker arm to drive NK cell proliferation, priming, and survival; and 3) a nanobody arm that specifically engages B7-H3 (camelid anti-B7-H3) to target the antigen expressed on tumor cells.
“This clearance is an important step toward developing new immune-based therapies for patients with advanced prostate cancer and other solid tumor types”, said Dr. Emmanuel Antonarakis, MD, Associate Director, Translational Research at the University of Minnesota Masonic Cancer Center1. “Given the high expression of B7-H3 in over 90% of metastatic castration-resistant prostate cancers and the unmet need in the patient population, I look forward to evaluating GTB-5550’s TriKE® approach in the upcoming Phase 1 trial. As part of our team, I am excited that Dr. Nicholas Zorko will be leading this clinical trial. He is emerging as a national leader in early phase immune engager clinical trials across oncology.”
The Phase 1 trial with GTB-5550 will be the first dual nanobody TriKE® tested with more patient-friendly subcutaneous dosing. The Phase 1a dose escalation portion of the trial will test up to 6 dose levels to identify the maximum tolerated dose (MTD). After the dose escalation phase , the Phase 1b expansion component of the trial will then confirm the MTD identified in the Phase 1a trial in up to 7 different possible metastatic disease cohorts (castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer) and further evaluate its safety, tolerability and preliminary anti-tumor activity.
GTB-5550 will be administered by subcutaneous (SQ) injection in the abdominal area for 5 consecutive days during Week 1 and Week 2 followed by 2 weeks of no treatment. One treatment cycle is 4 weeks in duration. A minimum of 2 cycles is planned, and patient-appropriate disease reassessment is performed after 2 cycles and every 8-12 weeks thereafter. Treatment may continue until disease progression, unacceptable toxicity, patient refusal, or treatment is no longer in the best interest of the patient. Patients are followed for 12 months to determine progression free survival (PFS) and overall survival (OS).
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
LinkedIn |Facebook |X |Instagram | YouTube
1 The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of product using the TriKE technology be realized, including GTB-3650 and GTB-5550. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.
FAQ**
How does GT Biopharma Inc. (GTBP) plan to prioritize patient enrollment for advanced prostate, ovarian, and pancreatic cancers in the GTB-5550 Phase 1 trial, and what criteria will be used for selecting eligible patients?
Can you elaborate on the anticipated benefits of GTB-5550 treatment for patients with solid tumors expressing B7-H3, as suggested by the ongoing Phase 1 trial with GTB-3650, and what preliminary results are expected to support this?
What are the safety and tolerability measures that GT Biopharma Inc. (GTBP) plans to implement during the dose escalation component of the GTB-5550 trial, and how will patient outcomes be monitored throughout the trial?
Considering the unaudited proforma cash balance of approximately $9 million as of January 31, 2026, how does GT Biopharma Inc. (GTBP) intend to manage its cash runway through Q4 2026 while progressing through the GTB-5550 trial phases?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
37.97% G/L:
$0.44 Last:
8,878,967 Volume:
$0.374 Open:
